Following government pronouncements on the Canada-EU trade talks (CETA)
GUELPH, ON, April 27, 2012 /CNW/ - "Canada must swiftly conclude negotiations with the European Union because Canadians and Canadian patients stand to benefit. Through CETA, we can foster Canada's health care innovation and grow our medical research leadership so that the patient voice I represent can benefit from critical medicines for patients living with depression, bipolar disorder, anxiety, schizophrenia and other mental illnesses.
The Mood Disorders Society of Canada stands alongside dozens of other organizations including the Canadian Chamber of Commerce and other patient and research groups in asking both jurisdictions to move swiftly towards a deal.
To be truly successful, CETA must protect Canadian innovation through stronger intellectual property safeguards which will help to attract investments and drive the research and development of medicines that are crucial for Canadian patients.
Canadian research has helped develop treatments that bring once-fatal illnesses under control, increase both life expectancy and quality of life, and reduce lengthy hospitalizations and the associated health care costs.
It is good to see ministers out talking to Canadians about the benefits of a trade deal between Canada and the EU - for too long has there been inflated noise about potential down sides to a deal. We heard the same noise years ago when NAFTA was negotiated, but the sky didn't fall then and it won't fall now."
For further information:
Available for interviews:
Philip C. Upshall - National Executive Director
Mood Disorders Society of Canada
3 -304 Stone Road West, Suite 736
Guelph, ON N1G 4W4